A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder

被引:129
作者
Yam, GHF [1 ]
Zuber, C [1 ]
Roth, J [1 ]
机构
[1] Univ Zurich, Dept Pathol, Div Cell & Mol Pathol, CH-8091 Zurich, Switzerland
关键词
chemical chaperone; protein misfolding disease; Fabry disease; alpha-galactosidase A; lysosomes;
D O I
10.1096/fj.04-2375com
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in proteins that induce misfolding and proteasomal degradation are common causes of inherited diseases. Fabry disease is a lysosomal storage disorder caused by a deficiency of alpha-galactosidase A activity in lysosomes resulting in an accumulation of glycosphingolipid globotriosylceramide (Gb3). Some classical Fabry hemizygotes and all cardiac variants have residual alpha-galactosidase A activity, but the mutant enzymes are unstable. Such mutant enzymes appear to be misfolded, recognized by the ER protein quality control, and degraded before sorting into lysosomes. Hence, correction of the trafficking defect of mutant but catalytically active enzyme into lysosomes would be beneficial for treatment of the disease. Here we show that a nontoxic competitive inhibitor (1-deoxygalactonojirimycin) of alpha-galactosidase A functions as a chemical chaperone by releasing ER-retained mutant enzyme from BiP. The treatment with subinhibitory doses resulted in efficient, long-term lysosomal trafficking of the ER-retained mutant alpha-galactosidase A. Successful clearance of lysosomal Gb3 storage and a near-normal lysosomal phenotype was achieved in human Fabry fibroblasts harboring different types of mutations. Small molecule chemical chaperones will be therapeutically useful for various lysosomal storage disorders as well as for other genetic metabolic disorders caused by mutant but nonetheless catalytically active enzymes.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 32 条
[1]  
BISHOP DF, 1981, AM J HUM GENET, V33, pA71
[2]   Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course [J].
Branton, MH ;
Schiffmann, R ;
Sabnis, SG ;
Murray, GJ ;
Quirk, JM ;
Altarescu, G ;
Goldfarb, L ;
Brady, RO ;
Balow, JE ;
Austin, HA ;
Kopp, JB .
MEDICINE, 2002, 81 (02) :122-138
[3]   The endoplasmic reticulum: integration of protein folding, quality control, signaling and degradation [J].
Chevet, E ;
Cameron, PH ;
Pelletier, MF ;
Thomas, DY ;
Bergeron, JJM .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2001, 11 (01) :120-124
[4]   Therapeutic approaches to protein-misfolding diseases [J].
Cohen, FE ;
Kelly, JW .
NATURE, 2003, 426 (6968) :905-909
[5]  
Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733, DOI DOI 10.1036/ommbid.181
[6]   Protein folding and misfolding [J].
Dobson, CM .
NATURE, 2003, 426 (6968) :884-890
[7]   Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells [J].
Egan, ME ;
Glöckner-Pagel, J ;
Ambrose, CA ;
Cahill, PA ;
Pappoe, L ;
Balamuth, N ;
Cho, E ;
Canny, S ;
Wagner, CA ;
Geibel, J ;
Caplan, MJ .
NATURE MEDICINE, 2002, 8 (05) :485-492
[8]   Quality control in the endoplasmic reticulum [J].
Ellgaard, L ;
Helenius, A .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (03) :181-191
[9]   Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor [J].
Fan, JQ ;
Ishii, S ;
Asano, N ;
Suzuki, Y .
NATURE MEDICINE, 1999, 5 (01) :112-115
[10]   The action of molecular chaperones in the early secretory pathway [J].
Fewell, SW ;
Travers, KJ ;
Weissman, JS ;
Brodsky, JL .
ANNUAL REVIEW OF GENETICS, 2001, 35 :149-191